{"log_id": 1781749457367876887, "direction": 0, "words_result_num": 47, "words_result": [{"probability": {"variance": 0, "average": 0.880624, "min": 0.880624}, "location": {"width": 26, "top": 87, "height": 25, "left": 1085}, "words": "监"}, {"probability": {"variance": 0.000175, "average": 0.979105, "min": 0.965874}, "location": {"width": 28, "top": 125, "height": 65, "left": 1098}, "words": "明缝"}, {"probability": {"variance": 0.001505, "average": 0.990729, "min": 0.762513}, "location": {"width": 670, "top": 197, "height": 46, "left": 172}, "words": "857例随机服用氟伐他汀钠缓释片的患者中,271例为原发性混合型血脂异常"}, {"probability": {"variance": 0.014324, "average": 0.947097, "min": 0.480835}, "location": {"width": 758, "top": 234, "height": 48, "left": 191}, "words": " Fredrickson I b型)基线TG≥200mg/d1,显示甘油三酯平均下降25%。同时,在这些患"}, {"probability": {"variance": 0.001021, "average": 0.990129, "min": 0.792324}, "location": {"width": 754, "top": 274, "height": 46, "left": 170}, "words": "者中,氟伐他汀钠缓释片使HDL-C明显增加13%。在HDL-C基线水平很低的患者中(即"}, {"probability": {"variance": 0.001903, "average": 0.980137, "min": 0.78861}, "location": {"width": 755, "top": 312, "height": 49, "left": 174}, "words": "35mg/dl),这种效应尤为明显,这些患者平均HDL-C增加了16%,同时TC、LDL-C及"}, {"probability": {"variance": 0.013391, "average": 0.946632, "min": 0.549027}, "location": {"width": 299, "top": 365, "height": 37, "left": 176}, "words": "po-B也出现了显著下降(见表4)"}, {"probability": {"variance": 0.01323, "average": 0.950969, "min": 0.515378}, "location": {"width": 378, "top": 353, "height": 37, "left": 521}, "words": "这些研究中排除了TG400mg/d1的患者。)"}, {"probability": {"variance": 2.7e-05, "average": 0.997592, "min": 0.972387}, "location": {"width": 676, "top": 392, "height": 45, "left": 212}, "words": "表424周后与基线水平相比的平均变化百分率(原发性混合型血脂异常)"}, {"probability": {"variance": 0, "average": 0.999024, "min": 0.998324}, "location": {"width": 46, "top": 447, "height": 25, "left": 299}, "words": "剂量"}, {"probability": {"variance": 0.003597, "average": 0.938095, "min": 0.878121}, "location": {"width": 21, "top": 443, "height": 23, "left": 510}, "words": "TC"}, {"probability": {"variance": 0.01322, "average": 0.918697, "min": 0.756092}, "location": {"width": 259, "top": 436, "height": 27, "left": 606}, "words": " DLC hdl-c apo-b"}, {"probability": {"variance": 1.1e-05, "average": 0.996771, "min": 0.992172}, "location": {"width": 42, "top": 483, "height": 21, "left": 502}, "words": "17%"}, {"probability": {"variance": 0, "average": 0.99927, "min": 0.999031}, "location": {"width": 33, "top": 481, "height": 22, "left": 609}, "words": "23"}, {"probability": {"variance": 0.001652, "average": 0.970741, "min": 0.900924}, "location": {"width": 42, "top": 475, "height": 22, "left": 817}, "words": "-17%"}, {"probability": {"variance": 3.2e-05, "average": 0.995711, "min": 0.987688}, "location": {"width": 40, "top": 473, "height": 21, "left": 923}, "words": "18%"}, {"probability": {"variance": 9e-06, "average": 0.996918, "min": 0.991745}, "location": {"width": 214, "top": 485, "height": 33, "left": 186}, "words": "氟伐他汀钠胶囊40毫克"}, {"probability": {"variance": 4e-06, "average": 0.998659, "min": 0.992056}, "location": {"width": 236, "top": 524, "height": 33, "left": 184}, "words": "氟伐他汀钠缓释片80毫克"}, {"probability": {"variance": 0.000597, "average": 0.982612, "min": 0.940551}, "location": {"width": 40, "top": 523, "height": 22, "left": 503}, "words": "-24%"}, {"probability": {"variance": 0, "average": 0.999582, "min": 0.999258}, "location": {"width": 22, "top": 522, "height": 20, "left": 627}, "words": "3%"}, {"probability": {"variance": 3.8e-05, "average": 0.993141, "min": 0.986969}, "location": {"width": 21, "top": 520, "height": 18, "left": 732}, "words": "3%"}, {"probability": {"variance": 0.015459, "average": 0.905209, "min": 0.729483}, "location": {"width": 23, "top": 516, "height": 22, "left": 831}, "words": "249"}, {"probability": {"variance": 1e-06, "average": 0.999303, "min": 0.997307}, "location": {"width": 170, "top": 553, "height": 31, "left": 179}, "words": "*平均变化的百分率"}, {"probability": {"variance": 0.000182, "average": 0.991224, "min": 0.951481}, "location": {"width": 497, "top": 623, "height": 38, "left": 177}, "words": "在脂蛋白和冠状动脉硬化研究中( Lipoprotein and Coronary"}, {"probability": {"variance": 0.002836, "average": 0.920941, "min": 0.811076}, "location": {"width": 171, "top": 615, "height": 29, "left": 783}, "words": " sis Study,LCAS),采"}, {"probability": {"variance": 5.9e-05, "average": 0.996625, "min": 0.96686}, "location": {"width": 794, "top": 652, "height": 49, "left": 176}, "words": "用定量冠状动脉造影术评估了氟伐他汀对冠状动脉粥样硬化过程的影响。年龄35~75岁患"}, {"probability": {"variance": 0.009847, "average": 0.972904, "min": 0.446861}, "location": {"width": 770, "top": 692, "height": 48, "left": 177}, "words": "轻中度高胆固醇血症(基线LDL-C为115~190mg/d1,)及冠状动脉粥样硬化性心脏病"}, {"probability": {"variance": 0.005611, "average": 0.9846, "min": 0.518706}, "location": {"width": 763, "top": 729, "height": 49, "left": 196}, "words": "CHD)的男女患者参加了这一随机双育安慰剂对照的临床研究,429例患者给予氟伐他"}, {"probability": {"variance": 0.008493, "average": 0.975648, "min": 0.517137}, "location": {"width": 780, "top": 767, "height": 50, "left": 179}, "words": "汀40mg/每天或安慰剂。在基线时和两年半时分别进行血管造影加以评估。结果显示氩伐"}, {"probability": {"variance": 0.001006, "average": 0.991958, "min": 0.82292}, "location": {"width": 750, "top": 805, "height": 50, "left": 180}, "words": "他汀治疗延缓了患者冠状动脉粥样硬化病变的进展,2.5年后最小管腔直径增加了0.07"}, {"probability": {"variance": 0.004745, "average": 0.970156, "min": 0.62571}, "location": {"width": 748, "top": 843, "height": 49, "left": 216}, "words": "95%可信区间,从-0.1222022)的变化。因此可将氟伐他汀钠用于延缓原发性高胆"}, {"probability": {"variance": 8.5e-05, "average": 0.997099, "min": 0.945516}, "location": {"width": 665, "top": 887, "height": 44, "left": 180}, "words": "固醇血症患者的冠状动脉粥样硬化的进展,包括轻度动脉粥样硬化和冠心病"}, {"probability": {"variance": 0.008484, "average": 0.969753, "min": 0.638583}, "location": {"width": 306, "top": 970, "height": 34, "left": 182}, "words": "氟伐他汀钠干预预防研究( Lescol In"}, {"probability": {"variance": 0.019409, "average": 0.924648, "min": 0.499491}, "location": {"width": 308, "top": 956, "height": 36, "left": 664}, "words": "Sudy,LIPS证实了氟伐他汀在冠状"}, {"probability": {"variance": 1e-06, "average": 0.999416, "min": 0.995635}, "location": {"width": 773, "top": 996, "height": 47, "left": 183}, "words": "动脉导管治疗后对主要不良心血管事件的二级预防作用。参加研究的冠心病患者年龄18"}, {"probability": {"variance": 0.007175, "average": 0.973357, "min": 0.573896}, "location": {"width": 795, "top": 1033, "height": 48, "left": 184}, "words": "80岁,基础胆固醇水平3.-.0mmol/L。这是一项随机、双盲、安慰剂对照试验,给予氟伐他"}, {"probability": {"variance": 0.00732, "average": 0.970576, "min": 0.57934}, "location": {"width": 782, "top": 1071, "height": 49, "left": 184}, "words": "汀N=844每天80mg治疗4年,与对照组(N=833)相比,氟伐他汀组显著减少了首次主要"}, {"probability": {"variance": 0.001648, "average": 0.987571, "min": 0.738294}, "location": {"width": 780, "top": 1108, "height": 51, "left": 185}, "words": "心血管事件MACE)达22%(p=0.013)。特别是在糖尿病和多支血管病变的患者中,这种益"}, {"probability": {"variance": 0.00454, "average": 0.979929, "min": 0.577414}, "location": {"width": 793, "top": 1149, "height": 47, "left": 185}, "words": "处更为突出。氟伐他汀可以显著降低心源性死亡和/或心肌梗死的危险达31%(p=0.065),因"}, {"probability": {"variance": 0.001001, "average": 0.993626, "min": 0.799338}, "location": {"width": 787, "top": 1187, "height": 48, "left": 184}, "words": "此可将氟伐他汀钠用于冠状动脉导管治疗后的二级预防,减少主要不良心血管事件的发生"}, {"probability": {"variance": 0.000187, "average": 0.995647, "min": 0.935675}, "location": {"width": 437, "top": 1235, "height": 38, "left": 195}, "words": "心源性死亡,非致死性心肌梗死和冠状动脉重建"}, {"probability": {"variance": 0, "average": 0.999806, "min": 0.999498}, "location": {"width": 84, "top": 1320, "height": 25, "left": 187}, "words": "儿童患者"}, {"probability": {"variance": 0.000216, "average": 0.992521, "min": 0.925898}, "location": {"width": 792, "top": 1340, "height": 46, "left": 187}, "words": "两项为期2年的开放性,剂量递增的试验(ZA01和2301)研究氟伐他汀20mg至80mg的"}, {"probability": {"variance": 5.4e-05, "average": 0.996599, "min": 0.961807}, "location": {"width": 746, "top": 1378, "height": 46, "left": 188}, "words": "安全性和有效性,总共有113例杂合子家族性高胆固醇血症的儿童和青少年患者参加"}, {"probability": {"variance": 1.3e-05, "average": 0.998196, "min": 0.983731}, "location": {"width": 726, "top": 1421, "height": 46, "left": 189}, "words": "试验入组的9岁及9岁以上的杂合子家族性高胆固醇血症患者应符合以下入选标准"}, {"probability": {"variance": 0, "average": 0.782689, "min": 0.782689}, "location": {"width": 160, "top": 1452, "height": 35, "left": 709}, "words": "分"}, {"probability": {"variance": 0.017664, "average": 0.912084, "min": 0.576958}, "location": {"width": 326, "top": 1475, "height": 29, "left": 259}, "words": "LDLC水平≥190mg/dL(49mmol/L)"}], "language": 3}